In summary, patients with FCS and recurrent pancreatitis have a very high morbidity with limited treatment options.[20] This case identifies a novel mutation causing severe FCS and is an example of a novel treatment modality using an RNA-inhibiting drug targeting apoCIII . The gene discussed is APOC3; the disease is pancreatitis.